Acurx Pharmaceuticals (NASDAQ:ACXP) Trading 0.7% Higher – Should You Buy?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)’s share price shot up 0.7% during mid-day trading on Wednesday . The stock traded as high as $1.3849 and last traded at $1.37. Approximately 58,591 shares changed hands during trading, a decline of 33% from the average daily volume of 87,142 shares. The stock had previously closed at $1.36.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Performance

The firm’s 50 day moving average is $1.44 and its 200-day moving average is $2.09. The firm has a market cap of $7.62 million, a price-to-earnings ratio of -0.51 and a beta of -2.02.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15). As a group, research analysts predict that Acurx Pharmaceuticals, Inc. will post -2 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.